Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01543919 · ClinicalTrials.gov registry record · Phase 2
Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide
A Phase 2 study of Pulmonary Disease, Chronic Obstructive, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 730
- Enrollment target
- 20
- Study locations
NCT01543919 is a Phase 2 study of Pulmonary Disease, Chronic Obstructive that has completed, run by Pfizer. The registered enrollment target is 730 participants, below the 1,034-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (29% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT01543919, a Phase 2 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 730 participants
- Enrollment target
- 20
- Study locations
Study Summary
PH-797804 is an oral anti-inflammatory drug that may reduce the inflammation that is associated with Chronic Obstructive Pulmonary Disease (COPD). PH-797804 will be dosed to patients with Chronic Obstructive Pulmonary Disease (COPD) to evaluate its potential safety and efficacy profile in Chronic Obstructive Pulmonary Disease (COPD)
Conditions Studied
Interventions
- DRUG PH-797804
Study Locations (20)
Florida
- Pfizer Investigational Site - Brandon
- Pfizer Investigational Site - Chiefland
- Pfizer Investigational Site - Chiefland
- Pfizer Investigational Site - Clearwater
- Pfizer Investigational Site - Clearwater
- Pfizer Investigational Site - New Port Richey
- Pfizer Investigational Site - Pensacola
- Pfizer Investigational Site - Tampa
- Pfizer Investigational Site - Williston
Alabama
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Birmingham
- Pfizer Investigational Site - Jasper
California
- Pfizer Investigational Site - Montclair
- Pfizer Investigational Site - San Diego
Arizona
- Pfizer Investigational Site - Phoenix
Connecticut
- Pfizer Investigational Site - Waterbury
Delaware
- Pfizer Investigational Site - Newark
Georgia
- Pfizer Investigational Site - Duluth
Kentucky
- Pfizer Investigational Site - Fort Mitchell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 730 participants |
| Start Date | 2012-04 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01543919
The ClinicalTrials.gov registry entry for NCT01543919 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 730 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,034-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (29% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 1 intervention - of which PH-797804 is the first listed.
NCT01543919 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT01543919 about?
NCT01543919 is a clinical study titled "Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium Bromide". PH-797804 is an oral anti-inflammatory drug that may reduce the inflammation that is associated with Chronic Obstructive Pulmonary Disease (COPD). PH-797804 will be dosed to patients with Chronic Obstructive Pulmonary Disease (COPD) to evaluate its potential safety and efficacy profile in Chronic Ob...
What is the current status of trial NCT01543919?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 730 participants. The study started on 2012-04. Estimated completion is 2013-09.
What conditions does trial NCT01543919 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT01543919?
The interventions under investigation include: PH-797804 (DRUG).
Who is sponsoring clinical trial NCT01543919?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01543919 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
COMPLETED · Phase 2
-
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD
COMPLETED · Phase 2
-
A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
COMPLETED · Phase 2
-
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.